2 results
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…
Approved WMORecruiting
Primary objectives: This study is two-fold and, therefore, has two primary objectives:1. Investigating the diagnostic accuracy of CLE (Cystoflex*F probe) during flexible cystoscopy for diagnosis and grading of urothelial carcinoma of the bladder.2.…